6.
Gordon R, Albornoz E, Christie D, Langley M, Kumar V, Mantovani S
. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018; 10(465).
PMC: 6483075.
DOI: 10.1126/scitranslmed.aah4066.
View
7.
Mao X, Terpolilli N, Wehn A, Cheng S, Hellal F, Liu B
. Progressive Histopathological Damage Occurring Up to One Year after Experimental Traumatic Brain Injury Is Associated with Cognitive Decline and Depression-Like Behavior. J Neurotrauma. 2019; 37(11):1331-1341.
DOI: 10.1089/neu.2019.6510.
View
8.
Hammond J, Bellizzi M, Ware C, Qiu W, Saminathan P, Li H
. Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav Immun. 2020; 87:739-750.
PMC: 8698220.
DOI: 10.1016/j.bbi.2020.03.004.
View
9.
Chhangani D, Martin-Pena A, Rincon-Limas D
. Molecular, functional, and pathological aspects of TDP-43 fragmentation. iScience. 2021; 24(5):102459.
PMC: 8113996.
DOI: 10.1016/j.isci.2021.102459.
View
10.
Corps K, Roth T, McGavern D
. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 2015; 72(3):355-62.
PMC: 5001842.
DOI: 10.1001/jamaneurol.2014.3558.
View
11.
Hutson C, Lazo C, Mortazavi F, Giza C, Hovda D, Chesselet M
. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma. 2011; 28(9):1783-801.
PMC: 3172882.
DOI: 10.1089/neu.2010.1723.
View
12.
Walker A, Spiller K, Ge G, Zheng A, Xu Y, Zhou M
. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015; 130(5):643-60.
PMC: 5127391.
DOI: 10.1007/s00401-015-1460-x.
View
13.
Laurent C, Dorothee G, Hunot S, Martin E, Monnet Y, Duchamp M
. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2016; 140(1):184-200.
PMC: 5382942.
DOI: 10.1093/brain/aww270.
View
14.
Yu H, Liu X, Chen B, Vickstrom C, Friedman V, Kelly T
. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease. Cells. 2021; 10(12).
PMC: 8700250.
DOI: 10.3390/cells10123548.
View
15.
Delage C, Taib T, Mamma C, Lerouet D, Besson V
. Traumatic Brain Injury: An Age-Dependent View of Post-Traumatic Neuroinflammation and Its Treatment. Pharmaceutics. 2021; 13(10).
PMC: 8537402.
DOI: 10.3390/pharmaceutics13101624.
View
16.
Maas A, Menon D, Manley G, Abrams M, Akerlund C, Andelic N
. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022; 21(11):1004-1060.
PMC: 10427240.
DOI: 10.1016/S1474-4422(22)00309-X.
View
17.
Taylor K, Saint-Hilaire M, Sudarsky L, Simon D, Hersh B, Sparrow D
. Head injury at early ages is associated with risk of Parkinson's disease. Parkinsonism Relat Disord. 2016; 23:57-61.
PMC: 4787263.
DOI: 10.1016/j.parkreldis.2015.12.005.
View
18.
Wang C, Yang T, Liang M, Xie J, Song N
. Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation. Transl Neurodegener. 2021; 10(1):39.
PMC: 8522040.
DOI: 10.1186/s40035-021-00265-y.
View
19.
Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Zhang G
. URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease. J Neuroinflammation. 2018; 15(1):137.
PMC: 5935963.
DOI: 10.1186/s12974-018-1172-y.
View
20.
Liao Y, Ma J, Dou J
. The Role of TDP-43 in Neurodegenerative Disease. Mol Neurobiol. 2022; 59(7):4223-4241.
DOI: 10.1007/s12035-022-02847-x.
View